TNF and cancer: Characteristics at the start of follow-up in the treatment cohorts: naïve (no treatment with thiopurines, tumor necrosis factors inhibitors (TNFi), and other targeted therapies), thiopurine (treatment with thiopurines), TNFi (treatment with TNFi), thiopurine + TNFi (overlapping treatment with thiopurine and TNFi), and treatment with vedolizumab, ustekinumab, and tofacitinib, in patients without a history of cancer.